Focus on expanding the delivery of controlled-substances in a microneedle patch. Evaluating potential uses of a microneedle patch for infectious diseases. Strengthening capabilities in the manufacturing of microneedle patches for FDA clinical studies and commercialization. TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM)…

Source

Previous articleMydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin
Next articleSilo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease